Phaseline

Targets › THRB

THRB (Thyroid hormone receptor beta): drug programs, companies and trials

11 programs from 11 companies in 21 trials: 8 Phase 2, 6 Phase 3, 5 Phase 4, 2 Phase 1; Metabolic and endocrine, Gastroenterology, Other; next expected readout Nov 2026.

Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. (UniProt, P10828)

Open in Phaseline: the race on THRB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Elyes KamounLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 4Hypothyroidism PrimaryDec 2026
Madrigal PharmaceuticalsResmetirom
Thyroid hormone receptor beta-1 agonist
THRBPhase 4MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH; Non-Alcoholic Fatty Liver Disease; NASH - Nonalcoholic Steatohepatitis …Dec 2026
University of PennsylvaniaLevothyroxine Sodium
Thyroid hormone receptor agonist
THRA, THRBPhase 4HypothyroidismApr 2028
Daihong LiuAnti-Thymocyte Globulin (ATG) (Thymoglobulin)
Anti-thymocyte immunoglobulin; depletes T cells through immune recognition
THRA, THRBPhase 4Hematopoietic Stem Cell TransplantationAug 2028
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 3ObesityNov 2026
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 3Hypothyroidism; IrradiationSep 2029
Rare Thyroid Therapeutics InternationalTiratricol
Thyroid hormone receptor agonist
THRA, THRBPhase 2Allan-Herndon-Dudley SyndromeJul 2027
AbbVieArmour Thyroid
Thyroid hormone replacement containing levothyroxine (T4) and liothyronine (T3)
THRA, THRBPhase 2HypothyroidismSep 2027
UConn HealthLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 2HypothyroidismDec 2027
VA Office of Research and DevelopmentLevothyroxine Sodium
Thyroid hormone receptor agonist
THRA, THRBPhase 2Nonalcoholic SteatohepatitisDec 2029
Sabine Mueller, MD, PhDLiothyronine (L-T3)
Thyroid hormone T3 receptor agonist for immunotherapy
THRBPhase 1MedulloblastomaMar 2031

Conditions

Hypothyroidism (4) Hematopoietic Stem Cell Transplantation (3) MASH - Metabolic Dysfunction-Associated Steatohepatitis (3) Hypothyroidism; Irradiation (1) NASH (1) Non-Alcoholic Fatty Liver Disease (1) NASH - Nonalcoholic Steatohepatitis (1) MASH (1) MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease (1) Hypothyroidism Primary (1) Obesity (1) Allan-Herndon-Dudley Syndrome (1)

Modalities

small molecule (9), protein or peptide (1), mixed (1)

Companies

Daihong Liu (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) Madrigal Pharmaceuticals (1) Elyes Kamoun (1) Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) Rare Thyroid Therapeutics International (1) AbbVie (1) University of Pennsylvania (1) Sabine Mueller, MD, PhD (1) UConn Health (1) VA Office of Research and Development (1)

Related targets

THRA (9)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.